EARLY WARNING NEWS RELEASE ISSUED PURSUANT TO NI 62-103
On May 7, 2025, Strong Global disposed of 213,860 common shares (the 'Disposed Shares' and each common share, a 'Common Share') of Saltire Capital Ltd. (the 'Issuer') which has a head office located at 1800 510 West Georgia St. Vancouver, British Columbia V6B 0M3. The Disposed Shares were sold through the facilities of the Toronto Stock Exchange. The sale of the Disposed Shares exceeded 2% of the issued and outstanding Common Shares of the Issuer and triggered the early warning reporting requirements under NI 62-103.
The Disposed Shares were sold at a price of $11.82 per Disposed Share and Strong Global received a total of $2,527,825.20 as consideration for the Disposed Shares.
The sale of the Disposed Shares represents a decrease of 3.7% in Strong Global's securityholding percentage in the Common Shares of the Issuer.
Prior to the sale of the Disposed Shares, Strong Global owned and controlled 1,972,723 Common Shares representing 34.18% of the then issued and outstanding Common Shares of the Issuer based on a total of 5,771,237 Common Shares outstanding as of May 7, 2025. Strong Global now holds 1,758,863 Common Shares representing 30.48% of the Common Shares of the Issuer.
The holdings of securities of the Issuer by Strong Global are managed for investment purposes. Strong Global may, in future, increase or decrease his ownership, control or direction over the Issuer's securities through market transactions, private agreements, or otherwise.
Strong Global will file an early warning report under the Issuer's profile on the SEDAR+ website at www.sedarplus.ca. A copy of the early warning report can also be obtained from the contact below:
Strong Global Entertainment, Inc.
108 Gateway Blvd
Suite 204 Mooresville, NC
United States.
About Strong Global Entertainment, Inc.
Strong Global Entertainment, Inc., a wholly-owned subsidiary of Fundamental Global Inc., is a leader in the entertainment industry, providing mission critical products and services to cinema exhibitors and entertainment venues for over 90 years.
SOURCE Strong Global Entertainment, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
2 hours ago
- Barnama
Voxela Officially Launches Next-Generation AI Eldercare Solution 'Voxela VCare Pro'
SAN FRANCISCO, Aug 7 (Bernama) -- Voxela, Inc. is pleased to announce the official release of its next-generation AI eldercare solution, 'Voxela VCare Pro'. The revolutionary VCare Pro significantly reduces operational burdens for caregivers while dramatically enhancing the safety and quality of life for elders within care facilities. Key Features of Voxela VCare Pro:
Malaysian Reserve
5 days ago
- Malaysian Reserve
OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025
BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ — OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH executive team will be presenting. Event Details Date: Wednesday, August 6, 2025Time: 8:00 a.m. ET / 2:00 p.m. CEST / 9:00 p.m. KSTLocation: Virtual (livestream access)Registration: Opens Monday, August 4 at Available after the event on the OSR Holdings Investor Relations website. Agenda Highlights Corporate overview and strategic vision Subsidiary and R&D pipeline updates: Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies Darnatein: DRT101 – a potent DMOAD candidate Woori IO acquisition: The opportunity for noninvasive CGM Equity Line of Credit (ELOC) financing strategy Blockchain & Tokenization strategy Live Q&A with management Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies Darnatein: DRT101 – a potent DMOAD candidate Woori IO acquisition: The opportunity for noninvasive CGM 'This event is a timely opportunity to engage with our shareholders and the broader investment community as we move into a transformative stage in OSR's growth,' said Peter Hwang, CEO of OSRH. 'We look forward to showcasing the strength of our platform, the progress we've made, and the catalysts ahead. We are committed to transparency, disciplined execution, and delivering meaningful value to all stakeholders in the coming months.'Featured Speakers: Mr. Peter Hwang – Chief Executive Officer Dr. Constance Höfer – Chief Scientific Officer Mr. Tim Smith – Global Investor Relations About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit
Malaysian Reserve
5 days ago
- Malaysian Reserve
Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
IRVINE, Calif. and QUEENSLAND, Australia, Aug. 1, 2025 /PRNewswire/ — ELIXIR MD, Inc., a pioneer in advanced medical technology and proprietary treatment protocols for plastic surgery, today announced the formation of its wholly owned subsidiary in Australia and New Zealand, alongside an exclusive partnership with High Tech Medical Pty Ltd. to launch the ELIXIR MD™ device across the region. Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.' Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.' Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph). About High Tech Medical Pty in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence. About ELIXIR MD, in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide.
